Anavex Life Sciences Corp.

Healthcare · Biotechnology · United States

Last price 1.19 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 110.31M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia;...